(Q42671884)

English

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

scientific article published on 10 July 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 November 2017

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial (English)

1 reference

Europe PubMed Central

4 November 2017

phase III clinical trial

0 references

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Kathleen M Dungan

1

1 reference

Europe PubMed Central

4 November 2017

Santiago Tofé Povedano

2

1 reference

Europe PubMed Central

4 November 2017

Thomas Forst

3

1 reference

Europe PubMed Central

4 November 2017

José G González González

4

1 reference

Europe PubMed Central

4 November 2017

Charles Atisso

5

1 reference

Europe PubMed Central

4 November 2017

Whitney Sealls

6

1 reference

Europe PubMed Central

4 November 2017

Jessie L Fahrbach

7

1 reference

Europe PubMed Central

4 November 2017

language of work or name

0 references

publication date

10 July 2014

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

384

1 reference

Europe PubMed Central

4 November 2017

9951

1 reference

Europe PubMed Central

4 November 2017

1349-1357

1 reference

Europe PubMed Central

4 November 2017

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ability to perform daily physical activities in individuals with type 2 diabetes and moderate obesity: a preliminary validation of the Impact of Weight on Activities of Daily Living Questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Test-retest, responsiveness, and minimal important change of the ability to perform physical activities of daily living questionnaire in individuals with type 2 diabetes and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Stepwise gatekeeping procedures in clinical trial applications.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

General multistage gatekeeping procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 receptor agonists: why is once weekly inferior to once daily?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960976-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(14)60976-4

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42671884&oldid=1965050117"